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Phellinus linteus is a fungus distributed throughout Japan, Korea and China. Boiled water-
soluble extracts from P. linteus (PLW) have shown anti-tumor and immunomodulatory
properties in experiments done by intraperitoneal treatment, or in in vitro cell cultures. This is
the first investigation on how oral administration of PLW influences immune responses. Here,
we established immunodeficient mice by mitomycin C (MMC) and then researched how PLW
influenced plaque-forming cell (PFC) production and populations of cytokine [interferon-
(IFNg-) and interleukin-4 (IL-4)]-producing T lymphocytes. PLW samples were administered
orally for 19 days (1, 2 or 4g/kg/day). PFC assay was followed using Jerne’s method. IFN- and
IL-4-producing T lymphocyte populations were measured by flow-activated cell sorter (FACS).
These assays were conducted the day after the last oral administration. MMC groups were
given MMC (1mg/kg/day) intraperitoneally for 6 days with PLW administration. The number
of PFC per 10
6 spleen cells increased significantly in the PLW (2g/kg/day) group when
compared with the MMC-control (P50.05) while populations of IFNg- and IL-4-producing
T lymphocytes decreased by MMC treatment. However, the PLW group tended to increase
more than the MMC-control. Our results indicated that PLW augments the immune response
of the spleen in MMC-induced immunodeficient mice.
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Introduction
In recent years, natural foods have become a vital part of
complementary and alternative medicine. Natural products
that show anti-tumor activity have been gaining popularity
among those faced with the deleterious side effects of
treatment using chemotherapeutic drugs or synthetic
compounds. In particular, a variety of mushrooms are
immune potentiators, and polysaccharides and peptides
with anti-tumor activity have been isolated from mush-
rooms (1) such as black mushroom shiitake, and Agaricus
blazei Murill (2–5). Among these, Phellinus linteus has
often been reported for its anti-tumor activity (6–13).
Distributed in Japan, Korea and China as an aqueous
extract, P. linteus is a traditional Kampo medicine for
diarrhea. Its major compounds are polysaccharides,
aminoacids, g-aminobutyric acid, vitamins and sugar.
Polysaccharides and proteoglycan isolated from P. linteus
exhibited cytotoxic action on tumor cells (9) and induced
functional maturation of murine dendritic cells (10,11).
The aqueous extract of P. linteus (PLW) inhibited IgE-
dependent mouse triphasic cutaneous reactions (12), and
stimulated antibody production (13). These studies, how-
ever, were done by intraperitoneal treatment, or in in vitro
cell culture system, and did not investigate the antibody
response to oral administration, which is a much more
convenient mode of treatment.
It is unclear how PLW activates the immune
system. Controlled by cytokine-producing T lymphocytes,
B lymphocytes appear to play an important role in the
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properly cited.immune response when it is inhibited by overwork,
stress, chemotherapeutic drugs and radiotherapy (14).
Immunodeficiency caused by anti-tumor drugs such as
mitomycin C (MMC) poses a serious problem for cancer
patients. MMC has strong anti-tumor activity, but also
restricts bone marrow activity (15–17). Therefore, patients
treated with MMC often develop a serious immunodefi-
ciency and it is for this condition that we considered the
potential of PLW. Since PLW has modulated the immune
response of Th1/Th2 cytokine secretion in murine
splenocytes (18,19) and Mossman proposed that Th1/
Th2 balance is associated with the immune system (20-22),
PLW treatment offered promise as a treatment for this
immunodeficient condition caused by MMC. We have
already established the mechanism of oral administration
of the mushroom by investigating how oral intake of
Kampo medicine and fungus augmented various immune
activities (23–27). We became convinced that PLW could
be used for this condition and established an immunodefi-
cient mouse model using MMC to investigate PLW’s
influence on the immune system.
Methods
Mice
Female C57BL/6J strain mice 8 weeks of age obtained from
Japan SLC (Hamamatsu, Japan), were bred and treated in
conformity with the guidelines for animal experiments at
Kanazawa Medical University. They were housed for 1
week with a 12h light–dark cycle in a temperature and
humidity controlled room, and were given free access to
food and water. After adaptation to the lighting conditions
for 1 week, healthy mice were chosen for the investigation.
Preparation of P. linteus
Mycelium of P. linteus was a gift from Iwata Chemical
Co., LTD. (Iwata, Japan). The boiled water extract
(abbreviated as PLW) was prepared as follows: 1kg of
the dried Mycelium was refluxed with 10l of water for
10h, and the aqueous extract was freeze-dried (375g,
37.5%). It was found to contain 6.4% protein, 83.2%
polysaccharide (4.4% of b-glucan) and under 0.1% fat.
Preparation of Mitomycin C-Induced
Immunodeficient Mice
Female mice 8 weeks of age were used. Mice in
MMC-treated groups received intraperitoneal injections
of MMC 1mg/kg/day of their body weight for 6 days
(28,29). According to a fixed rule, MMC medicine
(obtained from Kyowa Hakko Kogyo Co., Ltd, Tokyo,
Japan), was dissolved in distilled water. The control
group was injected with an equivalent volume of saline.
Weighing of the spleen and assay of its plaque-forming
cells (PFC) were done 1, 2, 3 and 4 weeks after MMC
treatment. The population of CD19-positive cells in the
spleen was measured 1 week after treatment by flow
cytometry.
Immunopotentiating Activity of PLW
in Immunodeficient Mice
The schedule is shown in Fig. 1. Mice were divided
into five groups (Control, MMC-control, MMC-PLW1,
MMC-PLW2 and MMC-PLW3). Control and
MMC-control groups were given distilled water, and
MMC-PLW groups were administered orally 1, 2 or
4g/kg/day of PLW for 19 days. MMC-groups were given
MMC (1mg/kg/day) intraperitoneally for 6 days with
PLW administration (28–30). The day after the last
administration, we measured weight change in the
spleen, researched PFC production and the population
of cytokine [interferon-g (IFNg) and interleukin-4
(IL-4)]-producing cells in the spleen.
PFC Production in Normal Mice Measured after
19 days of PLW
Female C57BL/6J mice were divided into four groups
(Control, PLW1, PLW2 and PLW3). The control group
was given distilled water and PLW groups were orally
administered 1, 2 or 4g/kg/day of PLW for 19 days. The
day after PLW treatments, we investigated change in
spleen weight and PFC production of spleen cells.
Assay of Plaque-Forming Cells
Sheep red blood cells (SRBC), used as antigens and
obtained from Japan Biomaterial Center (Tokyo, Japan),
were washed three times with saline. Mice received i.v.
injections of 1 10
8 SRBC. After 4 days, spleen cells
from these mice were centrifuged twice at 490g for 5min
and suspended in 10ml of 10% fetal calf serum, Roswell
Park Memorial Institute (FCS-RPMI) 1640 medium
(sigma, USA). Spleen cells were counted by Tulk test, a
standard method. The number of PFC against SRBC
antigen was determined by the method of Jerne et al.
(31). Briefly, 100ml aliquots of the spleen cell suspension
Figure 1. The experimental schedule of PLW on immune response.
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8% SRBC and 0.5% DEAE-Dextran (Pharmacia,
Sweden) in the final volume of 1.1ml. These samples
were incubated (37 C, 5% CO2, 2h) on the bottom layer
(Eagle’s minimum essential medium MEM agar). Guinea
pig serum, isolated from the blood of the Hartley guinea
pig, was added to the samples and incubated for 1h.
Hemolytic plaque of SRBC was counted by the naked
eye.
Analysis of Surface Antigens
The expression of surface antigens and cytokines in
spleen cells was determined by direct immunofluorescence
(32,33). Spleen cells (1 10
6 cells/100ml) were stained
with final 0.5mg of fluorescein-isothiocyanate (FITC)-
conjugated or phycoerythrin (PE)-conjugated monoclonal
antibody (mAb) at room temperature for 0.5h. The
FITC-conjugated anti-CD3 mAb, the PE-conjugated
anti-IFNg and -IL-4 mAb were obtained from Becton
Dickinson. After incubation, these cells were centrifuged
twice at 490g for 5min with 1ml of phosphate-based
solution (PBS) and suspended in 0.5ml of PBS contain-
ing 100mg/ml CaCl2/MgCl2, 0.01% sodium azide and 1%
FCS, and then analyzed using a FACScan flow cytometer
(Becton Dickinson, USA).
Statistical Analysis
All values expressed as means S.D. Data were statisti-
cally analyzed by one-way analysis of variance (ANOVA)
with the level of significance set at P50.05. Critical
differences between means were evaluated by Dunnett’s
multiple comparison test set at P50.05.
Results
Antibody Production after Mitomycin C Treatment
In researching augmentation of the immune response
to PLW administration in immunodeficient mice, we
investigated the recovery period from MMC-initiated
immunodeficiency. Results showed that PFC were not
produced 1 week after the last treatment. However,
production gradually recovered after 2 weeks (Fig. 2).
The numbers of PFC per 10
6 spleen cells in each period
were 88 27 (2 weeks), 261 145 (3 weeks), 371 144
(4 weeks), showing significant differences at 1 and
2 weeks against the control (P50.005). Spleen weight
at 1 week was lower than that of the control (P50.005).
There was no significant difference between the popula-
tions of CD19-positive cells in the spleen (Table 1),
suggesting that MMC treatment only slightly altered
the CD19-positive cell population. Since recovery from
immunodeficiency began 2 weeks after the last MMC
treatment, we decided to assay PFC and flow-activated
cell sorter (FACS) at that time.
Immunomodulating Activity of PLW in
Immunodeficient Mice
We examined how PLW influenced splenic weight and
PFC numbers per 10
6 spleen cells in immunodeficient
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Figure 2. Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1mg/kg/day, 6 days) on the weight of spleen (mg) and
the number of PFC per 10
6 spleen cells in normal mice. Each value represents the mean SD (n¼7); **P50.005 versus control.
Table 1. The population of CD19-positive cell 1 week after MMC
treatment in spleen cells
CD19-positive cells (%)
Control 50.5 2.5
MMC-1w 47.1 1.5
Each value represents the mean SD (n¼7).
eCAM 2008;5(1) 87mice. There was no significant difference among the
spleen weights of each group, as shown in Fig. 3. The
number of PFC per 10
6 spleen cells was 502 93
in the control, 118 80 (MMC-control), 184 49
(MMC-PLW1), 279 69 (MMC-PLW2) and 183 79
(MMC-PLW3), showing a significant difference between
the MMC-control and MMC-PLW2 (P50.05) and
suggesting that PLW augments antibody production in
immunodeficient mice.
Cytokine (IFNg and IL-4)-Producing T Lymphocytes
in Spleen Cells
FACS data is shown in Table 2. The population
of IFNg- and IL-4- producing T lymphocytes
decreased by MMC treatment while IFNg- and
IL-4-positive cells of PLW administration groups tended
to increase (without significance) compared with the
MMC-control. The population of CD3-positive cells was
unchanged.
PLW Administration Did Not Increase Antibody
Production in Normal Mice
Although PLW administration has shown immunopoten-
tiating activity for immunodeficient conditions, its
influence on normal conditions is unclear. Our results
on normal mice showed that the number of PFC per 10
6
spleen cells were 350 53 in the control, 448 78 in
PLW1, 446 131 in PLW2 and 383 101 in PLW3.
No significant differences were observed among any
of the groups, as shown in Fig. 4. PLW treatments for
19 days did not increase either antibody production or
spleen weight.
Discussion
As mentioned above, immunodeficiency is a serious side
effect of chemotherapeutic drugs. We considered that this
condition would be more receptive to PLW treatments
than normal conditions and normal mice appear to be
only slightly affected by PLW. Firstly, we made an
immunodeficient mouse model by MMC treatment. We
selected PFC assay in splenocytes as an index of immune
activity. This is a typical method to directly observe
antibody secreting cells. PFC production was completely
inhibited by MMC treatments (1mg/kg/day) for 6 days.
The condition continued for 1 week, and gradually
recovered without treatment. The spleen weights of the
MMC-1w group were considerably lower than the
control, and recovered completely after 2 weeks.
However, there was no significant difference in CD19
antigen positive cells between MMC-1w and the control.
This antigen exists on the cell surface membrane of
non-activated B lymphocytes (34) and the treatment did
not alter production suggesting that the maturation of
lymphocytes was being inhibited and would not change
during the treatment period.
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Figure 3. Effects of PLW treatments for 19 days on the weight of spleen (mg) and the number of PFC in mitomycin C-induced immunodeficient
mice. Each value represents the mean SD (n¼7); *P50.05 versus MMC-control.
Table 2. Effect of PLW oral administrarion for 19 days on
T lymphocyte subsets ratio in Mitomycin C-induced
immunodeficient mice
CD3 IFNg IL-4
Control 46.39 1.94 4.50 0.28 0.76 0.04
MMC-control 44.59 1.45 1.75 0.35 0.47 0.15
MMC-PLW1 47.24 6.93 2.11 0.47 0.78 0.29
MMC-PLW2 44.90 1.84 2.74 1.42 1.38 0.75
MMC-PLW3 47.81 0.60 2.22 0.11 2.69 0.75
Each value represents the mean SD (n¼4).
88 P. linteus extract in MMC-induced immunodeficient miceTo analyze how PLW administration altered immune
responses, we decided to assay 2 weeks after the last
MMC treatment. At this time, PFC production is
beginning to recover and the condition of the mouse is
closest to that of the immunodeficient patient. The
number of PFC per 10
6 spleen cells against SRBC
antigen was lower in the MMC-treated groups than in
the controls. However, the numbers almost doubled in
PLW-treated groups when compared with MMC-
controls, while there were no differences in spleen weights
of the two groups. The increase was not dose-dependent
with the most effective dosage being PLW 2g/kg. The
production of the 4g/kg group was lower than that of the
2g/kg group.
Since PLW administration enhanced antibody produc-
tion (mainly IgM), it was possible that IgG would be
elevated if the isotype switched from IgM to IgG in the
immunoglobulin. In spleens harvested from mice 4 days
after immunization, the population of IFNg or IL-4
antigen positive cells was lower in the MMC-control
than the control. However, these populations tended to
recover with PLW administration. IFNg antigens are
present on IFNg- producing T lymphocytes and IL-4
antigens are present on IL-4-producing T lymphocytes,
while CD3 antigens only exist on the cell surface
membrane of T lymphocytes. The production of IL-4
plays a role in B cell differentiation and it has been
suggested that the augmentation of antibody response
that occurs with PLW results from expansion of
IL-4-producing cells. Since IFNg- augments tumoricidal
activity (35) and induces functional maturation of
dendritic cells (10,11), the augmenting effect of
PLW may result from expansion of IFNg-producing
T lymphocytes, as has been reported in normal mice
(18,19).
The destruction of balance in the body leads to immune
disease (20–22) and PLW has the ability to change
Th1/Th2 balance and thus augment antibody production
in immunodeficient mice. Since PLW augments the
immune system, it may be used to prevent various
diseases. In correlation, it may be viable for strengthening
the immunodeficent condition of cancer patients.
However, further investigation of the immunopotentiat-
ing activity of PLW compounds is necessary.
References
1. Lindequist U, Niedermeyer TH, Julich WD. The pharmacological
potential of mushrooms. Evid Based Complement Alternat Med
2005;2:285–99.
2. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of
polysaccharide-protein complexes. Curr Med Chem 2000;7:715–29.
3. Hamuro J, Rollinghoff M, Wagner H. b(1-3)Glucan-mediated
augmentation of alloreactive murine cytotoxic T-lymphocytes
in vivo. Cancer Res 1978;38:3080–5.
4. Mizuno T, Wasa T, Ito H, Suzuki C, Ukai N. Antitumor-active
polysaccharides isolated from the fruiting body of Hericium
erinaceum, an edible and medicinal mushroom called yamabushitake
or houtou. Biosci Biotechnol Biochem 1992;56:347–8.
5. Mizuno M, Norimoto M, Minato K, Tsuchida H. Polysaccharide
from Agaricus blazei stimulate lymphocyte T-cell subsets in mice.
Biosci Biotechnol Biochem 1998;62:434–7.
6. Li G, Kim DH, Kim TD, Park BJ, Park HD, Park JI, et al.
Protein-bound polysaccharide from Phellinus linteus induces G2/M
phase arrest and apoptosis in SW480 human colon cancer cells.
Cancer Lett 2004;28;216:175–81.
7. Han SB, Lee CW, Jeon YJ, Hong ND, Yoo ID, Yang KH, et al.
The inhibitory effect of polysaccharides isolated from Phellinus
linteus on tumor growth and metastasis. Immunopharmacol 1999;
41:157–64.
8. Shibata Y, Kurita S, Okugi H, Yamanaka H. Dramatic remission
of hormone refractory prostate cancer achieved with extract of the
mushroom, Phellinus linteus. Urol Int 2004;73:188–90.
9. Kim GY, Oh YH, Park YM. Acidic polysaccharide isolated from
Phellinus linteus induces nitric oxide-mediated tumoricidal activity
of macrophages through protein tyrosine kinase and protein kinase
C. Biochem Biophys Res Commun 2003;309:399–407.
10. Kim GY, Han MG, Song YS, Shin BC, Shin YI, Lee HJ, et al.
Proteoglycan isolated from Phellinus linteus induces toll-like
receptors 2- and 4-mediated maturation of murine dendritic cells
via activation of ERK, p38, and NF-kB. Biol Pharm Bull
2004;27:1656–62.
11. Park SK, Kim GY, Lim JY, Kwak JY, Bae YS, Lee JD, et al.
Acidic polysaccharides isolated from Phellinus linteus induce
phenotypic and functional maturation of murine dendritic cells.
Biochem Biophys Res Commun 2003;312:449–58.
0
100
200
300
400
500
600
Weight of spleen (mg)
Control
PLW1
PLW2
PLW3
PFC/106 spleen cells
M
g
 
o
r
 
n
u
m
b
e
r
 
o
f
 
P
F
C
 
(
1
0
6
 
s
p
l
e
e
n
 
c
e
l
l
s
)
Figure 4. Effect of PLW oral administarion for 19 days on the weight of spleen and the number of PFC in normal mice. Each value represents the
mean SD (n¼8).
eCAM 2008;5(1) 8912. Inagaki N, Shibata T, Itoh T, Suzuki T, Tanaka H, Nakamura T,
et al. Inhibition of IgE-dependent mouse triphasic cutaneous
reaction by boiling water fraction separated from mycelium of.
Phellinus linteus. Evid Based Complement Alternat Med 2005;2:
369–74.
13. Song KS, Cho SM, Lee JH, Kim HM, Han SB, Ko KS, et al.
B-lymphocyte-stimulating polysaccharide from mushroom. Phellinus
linteus. Chem Pharm Bull 1995;43:2105–8.
14. Edwards AJ, Bacon TH, Elms CA, Verardi R, Felder M,
Knight SC. Changes in the population of lymphocyte cells in
human peripheral blood following physical exercise. Clin Exp
Immunol 1984;58:420–7.
15. Ohtake N, Suzuki R, Daikuhara H, Nakai Y. Modulation of lung
local immune responses by oral administration of a herbal medicine
Sho-saiko-to. Int J Immunopharmacol 2000;22:419–30.
16. Sugiura K. Studies in a tumor spectrum. VIII. The effect of
mitomycin C on the growth of a variety of mouse, rat, and hamster
tumors. Cancer Res 1959;19:438–45.
17. Kanamori H, Shima T, Morita C, Hara T. Studies on antitumor
activity of mitomycin. J Antibiotics 1957;10:120–7.
18. Lim BO, Yamada K, Cho BG, Jeon T, Hwang SG, Park T, et al.
Comparative study on the modulation of IgE and cytokine
production by Phellinus linteus grown on germinated brown Rice,
Phellinus linteus and germinated brown rice in murine splenocytes.
Biosci Biotechnol Biochem 2004;68:2391–4.
19. Lim BO, Jeon TI, Hwang SG, Moon JH, Park DK. Phellinus linteus
grown on germinated brown rice suppresses IgE production by the
modulation of Th1/Th2 balance in murine mesenteric lymph node
lymphocytes. Biotechnol Lett 2005;27:613–7.
20. Street NE, Mosmann TR. Functional diversity of T lymphocytes
due to secretion of different cytokine patterns. FASEB J 1991;
5:171–7.
21. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA,
CoVman RL. Two types of murine helper T cell clone. I.
Definition according to profiles of lymphokine activities and
secreted proteins. J Immunol 1986;196:2348–57.
22. Sad S, Mosmann TR. Single IL-2 secreting precursor CD4T cell
can develop into either Th1 or Th2 cytokine secretion phenotype.
J Immunol 1994;153:3514–22.
23. Kohno H, Jyumonji N, Yamaguchi N. An investigation of
the immune suppression induced by some Saikosaponin derivatives.
Int J Immnopharmacol 1988;10:845–50.
24. Miyazawa Y, Murayama T, Ooya N, Wang LF, Tung YC,
Yamaguchi N. Immunomodulation by a unicellular green algae
(Chlorella pyrenoidosa) in tumor-bearing mice. J Ethnopharmacol
1988;24:135–46.
25. Li AL, Komatsu Y, Ono Y, Nakatani F, Nakashima K,
Yamaguchi N. The effect of herbal medicines on the immuno-
deficient animals by injecting cancer chemotherapeutic agent-special
reference to age related recovery of the function. Kansenshogaku
Zasshi 1996;70:717–26.
26. Yamaguchi N, Yoshida J, Ren LJ, Chen H, Miyazawa Y, Fujii Y,
et al. Augmentation of various immune reactivities of tumor-
bearing hosts with an extract of Cordyceps sinensis. Biotherapy
1990;2:199–205.
27. Shimizu S, Kitada H, Yokota H, Yamakawa J, Murayama T,
Sugiyama K, et al. Activation of the alternative complement
pathway by Agaricus blazei Murill. Phytomedicine 2002;9:536–45.
28. Kiyohara H, Matsumoto T, Takemoto N, Kawamura H,
Komatsu Y, Yamada H. Effect of oral administration of a pectic
polysaccharide fraction from a kampo (Japanese herbal) medicine
‘‘juzen-taiho-to’’ on antibody response of mice. Planta Med
1995;61:429–34.
29. Takemoto N, Kiyohara H, Maruyama H, Komatsu Y, Yamada H,
Kawamura H. A novel type of B-cell mitogen isolated from
juzen-taiho-to (TJ-48), a Japanese traditional medicine. Int J
Immunopharmacol 1994;16:919–29.
30. Mitsuzumi H, Kusamiya M, Kurimoto T, Yamamoto I.
Requirement of cytokines for augmentation of antigen-specific
antibody responses by ascorbate in cultured murine T-cell depleated
splenocytes. Jpn J Pharmacol 1998;78:169–79.
31. Jerne NH, Nordin AA. Plaque formation in agar by single
antibody-producing cells. Science 1963;140:405.
32. Nicholson WA, Russian DA, Austen KF. Natural killer cells are
deficient in the surface expression of the complement regulatory
protein, decay accelerating fator(DAF). J Immunol 1986;137:1275–9.
33. Wang XX. Effect of physical exercise on leukocyte and lymphocyte
subpopulations in human peripheral blood. Cytometry Res
1998;8:53–61.
34. Krop I, Shaffer AL, Fearon DT, Schlissel MS. The signaling
activity of murine CD19 is regulated during cell development.
J Immunol 1996;157:48–56.
35. Kim GY, Oh WK, Shin BC, Shin YI, Park YC, Ahn SC, et al.
Proteoglycan isolated from Phellinus linteus inhibits tumor growth
through mechanisms leading to an activation of CD11cþCD8þ DC
and type I helper T cell-dominant immune state. FEBS Lett
2004;576:391–400.
Received December 6, 2005; accepted January 11, 2007
90 P. linteus extract in MMC-induced immunodeficient mice